WallStreetZenWallStreetZen

NASDAQ: SABS
Sab Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SABS

Based on 2 analysts offering 12 month price targets for Sab Biotherapeutics Inc

Min Forecast
$9.00+176.92%
Avg Forecast
$10.50+223.08%
Max Forecast
$12.00+269.23%

Should I buy or sell SABS stock?

Based on 2 analysts offering ratings for Sab Biotherapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SABS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SABS as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their SABS stock forecasts and price targets.

SABS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-19
lockedlocked$00.00+00.00%2025-09-17
lockedlocked$00.00+00.00%2025-07-22

1 of 1

Forecast return on equity

Is SABS forecast to generate an efficient return?

Company
N/A
Industry
237.05%
Market
142.96%

Forecast return on assets

Is SABS forecast to generate an efficient return on assets?

Company
N/A
Industry
106.32%

SABS earnings per share forecast

What is SABS's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$2.31
Avg 2 year Forecast
-$1.18
Avg 3 year Forecast
-$0.44

SABS revenue forecast

What is SABS's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
SABS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SABS revenue growth forecast

How is SABS forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
106.08%
Market
24.86%
SABS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SABS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SABS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SABS$3.25$10.50+223.08%Strong Buy
ITRM$0.67$9.00+1,243.28%Buy
TAOX$8.76N/AN/A
BTAI$2.05$26.67+1,200.83%Buy
NXTC$12.60$25.50+102.38%Strong Buy
View Top Biotech Stocks

Sab Biotherapeutics Stock Forecast FAQ

Is Sab Biotherapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SABS) stock is to Strong Buy SABS stock.

Out of 2 analysts, 1 (50%) are recommending SABS as a Strong Buy, 1 (50%) are recommending SABS as a Buy, 0 (0%) are recommending SABS as a Hold, 0 (0%) are recommending SABS as a Sell, and 0 (0%) are recommending SABS as a Strong Sell.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.

What is SABS's earnings growth forecast for 2025-2027?

(NASDAQ: SABS) Sab Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.

Sab Biotherapeutics's earnings in 2025 is -$34,276,337.On average, 8 Wall Street analysts forecast SABS's earnings for 2025 to be -$21,466,608, with the lowest SABS earnings forecast at -$35,512,866, and the highest SABS earnings forecast at -$7,219,649. On average, 8 Wall Street analysts forecast SABS's earnings for 2026 to be -$10,937,257, with the lowest SABS earnings forecast at -$37,789,332, and the highest SABS earnings forecast at -$3,122,010.

In 2027, SABS is forecast to generate -$4,132,018 in earnings, with the lowest earnings forecast at -$5,645,635 and the highest earnings forecast at -$2,439,070.

What is SABS's revenue growth forecast for 2025-2027?

(NASDAQ: SABS) Sab Biotherapeutics's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.

Sab Biotherapeutics's revenue in 2025 is $377,835.On average, 8 Wall Street analysts forecast SABS's revenue for 2025 to be $0, with the lowest SABS revenue forecast at $0, and the highest SABS revenue forecast at $0. On average, 8 Wall Street analysts forecast SABS's revenue for 2026 to be $0, with the lowest SABS revenue forecast at $0, and the highest SABS revenue forecast at $0.

In 2027, SABS is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SABS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SABS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 106.32%.

What is SABS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SABS price target, the average SABS price target is $10.50, with the highest SABS stock price forecast at $12.00 and the lowest SABS stock price forecast at $9.00.

On average, Wall Street analysts predict that Sab Biotherapeutics's share price could reach $10.50 by Sep 19, 2026. The average Sab Biotherapeutics stock price prediction forecasts a potential upside of 223.08% from the current SABS share price of $3.25.

What is SABS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SABS) Sab Biotherapeutics's current Earnings Per Share (EPS) is -$3.70. On average, analysts forecast that SABS's EPS will be -$2.31 for 2025, with the lowest EPS forecast at -$3.82, and the highest EPS forecast at -$0.78. On average, analysts forecast that SABS's EPS will be -$1.18 for 2026, with the lowest EPS forecast at -$4.07, and the highest EPS forecast at -$0.34. In 2027, SABS's EPS is forecast to hit -$0.44 (min: -$0.61, max: -$0.26).

What is SABS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SABS) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.